PATAS - AdipoPharma
Alternative Names: PATAS trifluoroacetate; Peptide derived from PKC alpha Targeting AlmS - AdipoPharma; Peptide-mimic of PKC Alpha Targeting ALMS - AdipoPharmaLatest Information Update: 02 Feb 2026
At a glance
- Originator INSERM; Monash University; University of Birmingham; University of Strasbourg
- Developer AdipoPharma
- Class Antihyperglycaemics; Peptides
- Mechanism of Action Adipocyte modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 27 Jan 2026 Phase-I clinical trials in Type 2 diabetes mellitus (In volunteers) in USA (SC) (NCT07223333)
- 31 Oct 2025 AdipoPharma plans a phase I trial for Type 2 diabetes mellitus (In volunteers) in USA (SC) (NCT07223333)
- 11 Nov 2024 AdipoPharma plans a phase I trial for Type 2 diabetes mellitus, in mid-2025